The caveman skincare trend on TikTok is clean beauty at its worst
The idea is that it's an elimination diet for your skin; an epidermal reset, if you will. 'For years, I picked and over-exfoliated and damaged my skin really badly … My skin is basically shedding all the damage and attempting to reregulate itself,' Zakher says in a video about the trend. Over the course of her attempt, which she says she did with guidance from her dermatologist, her skin looks as if it's pilling and then peeling off.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
16 hours ago
- Cision Canada
Imfinzi approved in Canada as first and only perioperative immunotherapy for muscle invasive bladder cancer Français
MISSISSAUGA, ON, Aug. 6, 2025 /CNW/ - Health Canada has granted a Notice of Compliance (NOC) for Imfinzi ® (durvalumab) for the treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant Imfinzi monotherapy treatment after radical cystectomy. The approval is based on results from the NIAGARA Phase III trial, which were published in The New England Journal of Medicine. 1, 2 In a planned interim analysis, the Imfinzi-based perioperative regimen demonstrated a statistically significant and clinically meaningful 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death versus neoadjuvant chemotherapy with radical cystectomy alone (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001). Estimated median EFS was not yet reached for the Imfinzi plus gemcitabine and cisplatin arm versus 46.1 months for the comparator arm. An estimated 67.8% of patients treated with the regimen were event free at two years compared to 59.8% in the comparator arm. 2 Results from the key secondary endpoint of overall survival (OS) showed that the Imfinzi-based perioperative regimen reduced the risk of death by 25% versus the comparator arm (based on OS HR of 0.75; 95% CI 0.59-0.93; p=0.011). Median survival was not yet reached for either arm. An estimated 82.2% of patients treated with the regimen were alive at two years compared to 75.2% in the comparator arm. 2 Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. The most common adverse events (any Grade, occurring in ≥10% of patients) for the Imfinzi plus chemotherapy arm were nausea (53.6%), fatigue (51.5%), neutropenia (40.4%), anemia (38.7%), constipation (38.7%), decreased appetite (26.6%), rash (20.9%), pyrexia (20.8%), diarrhea (20.6%), abdominal pain (20.2%), vomiting (19.2%), blood creatine increased (18.5%), thrombocytopenia (17.2%), pruritus (15.1%), hypothyroidism (12.6%), neuropathy peripheral (12.5%), leukopenia (10.9%), and aspartate aminotransferase increased (10.4%). 1 "Health Canada's approval of this durvalumab-based perioperative regimen represents a major advance for Canadians with muscle invasive bladder cancer, where nearly half will relapse despite curative treatment," says Dr. Srikala Sridhar, Professor of Medicine at the University of Toronto, Genitourinary Medical Oncologist at the Princess Margaret Cancer Centre and NIAGARA trial investigator. "Findings from the NIAGARA trial showed that this new regimen reduces risk of recurrence and significantly improves survival – which may offer new hope and potential to transform care in this setting." "The high rate of recurrence associated with muscle invasive bladder cancer is an ongoing challenge and source of concern for physicians and patients," says Dr. Normand Blais, Medical Oncologist at the Centre hospitalier de l'Université de Montréal. "The Health Canada approval based on results from the NIAGARA trial may now offer us the opportunity to increase the chance of better patient outcomes and long-term survival by the use of immunotherapy in this setting, which is very good news for patients and their families." Bladder cancer is the 5th most common cancer in Canada, with more than 13,000 patients diagnosed each year. 3 The most common type of bladder cancer is urothelial carcinoma, which begins in the urothelial cells of the urinary tract. Bladder cancer is considered muscle invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases. 4 In MIBC, approximately 50% of patients who undergo bladder removal surgery experience disease recurrence. 5 Treatment options that prevent disease recurrence after surgery are critically needed in this curative-intent setting. "This decision by Health Canada represents an important step forward for all Canadians affected by muscle invasive bladder cancer," says Michelle Colero, Executive Director, Bladder Cancer Canada. "For many patients and families, the fear of recurrence after surgery has been overwhelming. This new treatment option may offer renewed hope for longer, healthier lives." About NIAGARA 2 NIAGARA is a randomized, open-label, multi-centre, global Phase III trial evaluating perioperative Imfinzi as treatment for patients with MIBC before and after radical cystectomy. In the trial, 1,063 patients were randomized to receive four cycles of Imfinzi plus neoadjuvant chemotherapy prior to cystectomy followed by eight cycles of Imfinzi monotherapy, or neoadjuvant chemotherapy alone prior to cystectomy with no further treatment after surgery. NIAGARA is the largest global Phase III trial in this setting to date. The trial is being conducted at 192 centres in 22 countries across North America (including Canada), South America, Europe, Australia and Asia. Its dual primary endpoints are EFS and pathologic complete response at the time of cystectomy. Key secondary endpoints are OS and safety. About Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer. AstraZeneca is committed to contributing to a more sustainable future for people, society and planet taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at Imfinzi ® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under license by AstraZeneca Canada Inc. SOURCE AstraZeneca Canada Inc.
Cision Canada
16 hours ago
- Cision Canada
MaRS and Toyota Mobility Foundation select participants for the Mobility Unlimited Hub's second cohort
These 10 high-potential startups are working on affordable prosthetics, smart exoskeletons and other innovative solutions to support active mobility. TORONTO, Aug. 6, 2025 /CNW/ - MaRS Discovery District and the Toyota Mobility Foundation (TMF) today announced the 10 high-potential startups that will be participating in the second cohort of the Mobility Unlimited Hub (MUH) in Toronto. These companies bring novel technological approaches to active mobility and transformational devices and will leverage the Hub's network to accelerate the commercialization of their solutions in both Canada and globally. Building on the success of the first cohort, this program is once again focused on active mobility, including rehabilitative, adaptive and assistive solutions, with the aim of fostering a more inclusive and accessible society. The human-centered philosophy behind the MUH is simple: When people are free to move, they can fully realize their potential. The power of the ecosystem The MUH was launched in Toronto in 2024, in response to a clear need. According to a recent Canadian Survey on Disability, 27 percent of Canadians aged 15 years and older — eight million people — have one or more disabilities that limit their daily activities. Additionally, 30 percent of people living with disabilities in Canada report that their requirements for assistive devices have not been fulfilled. After receiving more than 70 applications from across the globe, MaRS and TMF, along with their advisory committee, have selected 10 innovative startups to participate in the second cohort. The new MUH cohort members include: Bionic Power Inc. - This Vancouver-based startup has developed a smart orthosis to address knee-related gait deficiencies, allowing people with cerebral palsy, spina bifida and post-polio syndrome to move more easily, safely and independently. GiveVision - This London, U.K. startup has developed sight-enhancing wearable headsets that allow visually impaired users to watch live sports and cultural events. Human in Motion Robotics Inc. - This Vancouver-based startup has developed a wearable self-balancing lower‑limb exoskeleton designed for rehabilitation and personal mobility. ImaginAble Solutions Inc. - This Hamilton-based startup has developed an assistive device to help people with limited hand mobility write, draw, paint and use touchscreens. Kinesix XR Inc. - This Montreal- and Chile-based startup leverages virtual reality and augmented reality technologies to deliver AI-powered rehabilitation therapy for patients recovering from strokes and traumatic brain injuries and those living with Parkinson's disease, multiple sclerosis (MS), chronic pain and other ongoing conditions. Ora Medical Inc. - This Montreal-based startup has developed a hands-free gait trainer designed to support walking rehabilitation for children with mobility challenges. Possibility Neurotechnologies - This Calgary-based startup has developed a mobile app that transforms EEG headsets into brain-computer interfaces, allowing users to control devices and communicate using only their thoughts. smartARM Robotics Inc. - This Toronto-based startup has developed an intuitive, affordable, AI-powered bionic arm with vision-based grip recognition. Steadiwear - This Toronto-based startup has developed hand-stabilization gloves to assist adults with tremors, including those caused by Parkinson's disease and strokes. Victoria Hand Project - This Victoria-based non-profit partners with local clinics to manufacture 3D-printed upper-limb prosthetics for amputees in low-resource and conflict-affected regions. "Mobility means moving forward with new ideas. Our first cohort proved the power of the community to scale new active mobility solutions faster and more effectively, and bring needed change to the industry," says William Chernicoff, program manager at Toyota Mobility Foundation. "Founded on a commitment to human-centred design, the Hub was created to position this market as one worth investing in, and we are seeing that transformation. There remains a wide range of unmet needs and challenges that limit active mobility, which is why we are expanding the next cohort's scope to allow for more diversity in the problems the startups are seeking to solve." Critical to the MUH's success is the ongoing commitment from MaRS Discovery District, which includes expanded access to state-of-the-art working spaces at the MaRS Centre in downtown Toronto. This highly effective collaboration demonstrates that change can happen rapidly in the context of a holistic ecosystem designed to drive innovation in active mobility. "The Mobility Unlimited Hub is more than a program — it's a powerful example of what happens when innovation is driven by purpose," says Morgan Lorimer, senior manager of cohort programs in innovation ecosystems at MaRS. "With a new dedicated co-working space at the MaRS Centre, we're creating the environment these startups need to scale, turning bold ideas into inclusive mobility solutions that improve lives and expand access." "Joining this cohort is a game changer for ImaginAble Solutions as we enter our next phase of growth, scaling Guided Hands® to reach more children and adults with hand disabilities around the world," says Lianna Genovese, CEO and founder of ImaginAble Solutions Inc., part of the new MUH cohort. "Access to industry experts in manufacturing and research will accelerate our ability to expand into schools, hospitals, and homes." Entrepreneurs speed toward scalability The first cohort's successes far exceeded the initial expectations held by both participants and program organizers, demonstrating that the path from early-stage innovation to market scale can be accelerated with the right combination of resources. Those resources include marketing and public relations support, funding opportunities, regulatory advice and guidance to improve manufacturing efficiency and supply chain optimization. "The Mobility Unlimited Hub has been instrumental in accelerating our growth. The opportunity to collaborate with others in the mobility space has enhanced our production capabilities and streamlined our business processes, ultimately delivering a better experience for our customers," says Eugene Cherny, CEO and co-founder of Cheelcare, a member of the inaugural MUH cohort. Since the inception of this program, startup members have hit key milestones. Highlights include: More than $8.1 million in funding secured across the cohort. AWL-Electricity established a partnership with Infineon Technologies, Germany's largest semiconductor manufacturer, gaining a global distribution partner to revolutionize wireless power transmission. Axtion Independence Mobility secured agreements with distribution partners across Canada, the European Union, United Kingdom and the United States, facilitating the venture's entry into the market in the fall of 2025. Braze Mobility Inc. received two patents, helping the company expand into Europe and scale in the U.S. Cheelcare raised $3.5 million and is now publicly listed on the TSX Venture Exchange following its reverse takeover of Departure Bay Capital Corp. Deaf AI secured multi-year R&D funding from Transport Canada, NSERC and Mitacs, in partnership with top academic institutions, including the University of British Columbia, Toronto Metropolitan University and Sheridan College. Trexo Robotics Inc. users have taken more than 100 million steps — a giant leap in the company's mission to help children with mobility challenges gain independence. Visit the Mobility Unlimited Hub web page for more information about the program. About Toyota Mobility Foundation The Toyota Mobility Foundation (TMF) was established in August 2014 by the Toyota Motor Corporation (TMC) to support the development of a more mobile society in which everyone can move freely. The Foundation underscores TMC's ongoing commitment to continuous improvement and respect for people. It utilizes Toyota's expertise and technologies to support strong mobility systems while eliminating disparities in mobility. TMF works in partnership with universities, governments, non-profits, research institutions and other organizations, creating programs that are aligned with the UN Sustainable Development Goals (SDGs) to address mobility issues around the world. About MaRS Discovery District MaRS Discovery District is a charitable organization and North America's largest urban innovation hub dedicated to helping Canadian technology companies succeed. With a focus on climate, health sciences and other emerging technologies, MaRS supports startups tackling some of the world's most pressing issues. MaRS spans more than 1.5 million square feet of cutting-edge office, lab, meeting and event space in downtown Toronto. MaRS has helped ventures generate $11.5 billion in cumulative revenue, raise $19 billion in funding, and create and maintain more than 33,000 jobs. The MaRS platform also includes MaRS IAF, one of Canada's top seed-stage venture funds. Through its world-class facilities, strategic programs and partnerships, MaRS accelerates the adoption of groundbreaking Canadian technology and bolsters a globally competitive innovation ecosystem.
CTV News
16 hours ago
- CTV News
Paralyzed Montreal firefighter to finally undergo eye surgery after accessibility gaps
Michael Lavigne, a former Montreal firefighter paralyzed by a stroke is unable to get cataract surgery because no clinic can accommodate his medical needs. A Montreal man living with disabilities after suffering a stroke three years ago has just found out that he will be able to undergo surgery for cataracts. Following a story by CTV News about Michael Lavigne's plight, a transport company in the eastern Ottawa area, Salutem, reached out to offer to take him to a clinic for testing in September. This comes after Lavigne, a former Montreal firefighter, was told that there wasn't a clinic that could accommodate his bulky medical equipment, preventing him from getting preliminary testing ahead of surgery. READ MORE: Paralyzed Montreal firefighter unable to get eye surgery due to accessibility gaps He had originally been scheduled for cataract surgery before his stroke, but now bedridden, Lavigne requires a lift to sit up and a special ambulance to leave the house. Though his brain functions normally, his speech is limited, and he struggles to articulate his thoughts. He is cared for full-time by his mother and sister, as well as a CLSC nurse who visits him at home. 'Each hospital said the same thing, that they can do the surgery, but that the testing had to be done at an outside facility,' explained his mother, Connie Auger. 'They then gave me the numbers to call these facilities, and when I explained his condition and the severity of his paralysis, they said they could not help him because he cannot sit by himself.' Once the tests are complete, Lavigne is expected to be scheduled for surgery at Lachine Hospital.
